Abstract:Objectives The effects of myricetin, a natural flavonoid, on the pharmacokinetics of losartan and its active metabolite, EXP-3174, were investigated in rats. Losartan and myricetin interact with cytochrome P450 (CYP) enzymes and P-glycoprotein, and the increase in the use of health supplements may result in myricetin being taken concomitantly with losartan as a combination therapy to treat or prevent cardiovascular diseases.Methods The pharmacokinetic parameters of losartan and EXP-3174 were determined after oral administration of losartan (9 mg/kg) to rats in the presence or absence of myricetin (0.4, 2 and 8 mg/kg). The effects of myricetin on P-glycoprotein as well as CYP3A4 and CYP2C9 activity were also evaluated.Key findings Myricetin inhibited CYP3A4 and CYP2C9 enzyme activity with a 50% inhibition concentration of 7.8 and 13.5 mu m, respectively. In addition, myricetin significantly enhanced the cellular accumulation of rhodamine 123 in MCF-7/ADR cells overexpressing P-glycoprotein in a concentration-dependent manner. The pharmacokinetic parameters of losartan were significantly altered by myricetin compared with the control. The presence of myricetin (2 or 8 mg/kg) increased the area under the plasma concentration-time curve of losartan by 31.4-61.1% and peak plasma concentration of losartan by 31.8-50.2%. Consequently, the absolute bioavailability of losartan in the presence of myricetin increased significantly (P < 0.05, 2 mg/kg; P < 0.01, 8 mg/kg) compared with the control. There was no significant change in the time to reach the peak plasma concentration, apparent volume of distribution at steady state or terminal half-life of losartan in the presence of myricetin. Furthermore, concurrent use of myricetin (8 mg/kg) significantly decreased the metabolite- parent area under the plasma concentration-time curve ratio by 20%, implying that myricetin may inhibit the CYP-mediated metabolism of losartan to its active metabolite, EXP-3174.Conclusions The enhanced bioavailability of losartan may be mainly due to inhibition of the CYP3A4- and CYP2C9-mediated metabolism of losartan in the small intestine or in the liver, and the P-glycoprotein efflux pump in the small intestine by myricetin.

Effect of Silymarin on the Pharmacokinetics of Losartan and Its Active Metabolite E-3174 in Healthy Chinese Volunteers

Effects of the CYP2C9*13 allele on the pharmacokinetics of losartan in healthy male subjects.

ABCB1 Haplotype Influences the Sirolimus Dose Requirements in Chinese Renal Transplant Recipients.

Effect of continuous silymarin administration on oral talinolol pharmacokinetics in healthy volunteers.

Effect of Soy Extract Administration on Losartan Pharmacokinetics in Healthy Female Volunteers

Cyp2c9*3 Allelic Variant is Associated with Metabolism of Irbesartan in Chinese Population

Effect of Silymarin Supplement on the Pharmacokinetics of Rosuvastatin

Effect of 36 CYP2C9 Variants Found in the Chinese Population on Losartan Metabolismin Vitro

Enzymatic Activity on Valsartan of 38 CYP2C9 Variants from the Chinese Population

Effects of Cyp2c19 Polymorphism on the Pharmacokinetics of Lansoprazole and Its Main Metabolites in Healthy Chinese Subjects

The Influence of UGT2B7, UGT1A8, MDR1, ALDH, ADH, CYP3A4 and CYP3A5 Genetic Polymorphisms on the Pharmacokinetics of Silodosin in Healthy Chinese Volunteers

Differences in CYP3A41G Genotype Distribution and Haplotypes of CYP3A4, CYP3A5 and CYP3A7 in 3 Chinese Populations.

Effects of Myricetin, an Antioxidant, on the Pharmacokinetics of Losartan and Its Active Metabolite, EXP-3174, in Rats: Possible Role of Cytochrome P450 3A4, Cytochrome P450 2C9 and P-glycoprotein Inhibition by Myricetin.

The effect of CYP2C19 activity on pharmacokinetics of lansoprazole and its active metabolites in healthy subjects.

No effect of MDR1 C3435T polymorphism on oral pharmacokinetics of telmisartan in 19 healthy Chinese male subjects.

Effect of CYP2C19 genetic polymorphism on pharmacokinetic characterstics and 5-hydroxyl metabolic pathway of lansoprazole in Chinese volunteers

CYP2C9 Ile359Leu Polymorphism, Plasma Irbesartan Concentration and Acute Blood Pressure Reductions in Response to Irbesartan Treatment in Chinese Hypertensive Patients.

In vitro assessment of the effects of silybin on CYP2B6-mediated metabolism

Effects of Genetic Variants in UGT1A1, SLCO1B3, ABCB1, ABCC2, ABCG2, ORM1 on PK/PD of Telmisartan in Chinese Patients with Mild to Moderate Essential Hypertension

Effect of Cytochrome P450 Oxidoreductase Ala503Val Genotype on the Pharmacokinetics of Amlodipine in Healthy Chinese Subjects

Effect of Glycyrrhizin on CYP2C19 and CYP3A4 Activity in Healthy Volunteers with Different CYP2C19 Genotypes